Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure

Table 5 90-day mortality and other secondary outcomes in primaquine versus non-primaquine group, and caspofungin versus non-caspofungin group

	Non-primaquine, n = 31	Primaquine, n = 18	χ.² value	P value	SMD	OR
Before controlled
90-day mortality, n (%)	19 (61.3)	10 (55.6)	0.155	0.926	0.117	0.789 (0.243, 2.563)
In-hospital mortality, n (%)	18 (58.1)	9 (50.0)	0.299	0.803	0.162	0.722 (0.225, 2.321)
28-day mortality, n (%)	13 (41.9)	7 (38.9)	0.044	1.000	0.062	0.881 (0.269, 2.885)
Overall death, n (%)	20 (64.5)	11 (61.1)	0.057	1.000	0.070	0.864 (0.260, 2.869)
After controlled
90-day mortality, n (%)	20.0 (64.6)	8.3 (45.9)	1.873	0.171	0.381	0.467 (0.143, 1.517)
In-hospital mortality, n (%)	19.0 (61.1)	7.9 (43.7)	1.306	0.253	0.355	0.493 (0.153, 1.596)
28-day mortality, n (%)	14.3 (46.0)	6.3 (34.8)	0.660	0.417	0.229	0.627 (0.190, 2.070)
Overall death, n (%)	21.1 (67.9)	8.8 (48.8)	1.510	0.219	0.394	0.451 (0.137, 1.481)

	Non caspofungin, n = 22	Caspofungin, n = 27	χ.² value	P value	SMD	OR
Before controlled
90-day mortality, n (%)	10 (45.5)	19 (70.4)	3.115	0.078	0.522	2.850 (0.878, 9.252)
In-hospital mortality, n (%)	9 (40.9)	18 (66.7)	3.251	0.071	0.535	2.889 (0.899, 9.283)
28-day mortality, n (%)	7 (31.8)	13 (48.2)	1.338	0.247	0.338	1.990 (0.616, 6.427)
Overall death, n (%)	11 (50.0)	20 (74.1)	3.023	0.082	0.512	2.857 (0.861, 9.483)
After controlled
90-day mortality, n (%)	4.8 (21.8)	17.5 (64.6)	8.607	0.003	0.958	6.549 (1.850, 23.180)
In-hospital mortality, n (%)	3.9 (17.7)	14.9 (55.2)	6.944	0.008	0.846	5.730 (1.565, 20.976)
28-day mortality, n (%)	3.2 (14.4)	11.0 (40.7)	4.235	0.040	0.616	4.079 (1.036, 16.070)
Overall death, n (%)	5.2 (23.4)	18.5 (68.4)	10.456	0.001	1.012	7.085 (1.999, 25.105)

ISSN: 1471-2334